HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FAC infant formula, take two

This article was originally published in The Tan Sheet

Executive Summary

FDA's Food Advisory Committee will meet June 20-21 to discuss "scientific issues and principles involved in assessing and evaluating whether a 'new' infant formula supports normal physical growth in infants when consumed under its intended conditions of use." Meeting is second in a series to assess infant formula quality issues; first took place April 4-5 (1"The Tan Sheet" April 8, 2002, p. 3). FAC will meet at the Holiday Inn, 1000 Baltimore Ave., College Park, Md. For more information, contact CFSAN's Constance Hardy at (301) 436-1433...

You may also be interested in...



Infant formula meeting canceled

FDA Food Advisory Committee meeting on infant formula scheduled for June 20-21 was canceled due to unavailability of some speakers, agency says. Meeting was to be second in series on quality issues ("1The Tan Sheet" June 3, 2002, In Brief). Rescheduling is planned, but dates have yet to be determined...

Infant Formula Data Generalizations Inappropriate In Most Cases – FAC

Data on preterm infants should not be applied to term infants in the majority of cases, but exceptions may arise on an individual basis, FDA's Food Advisory Committee said April 4-5

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel